# Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

> **NCT03531918** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 66 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **DRUG:** Gemtuzumab Ozogamicin
- **BIOLOGICAL:** Recombinant Granulocyte Colony-Stimulating Factor
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mitoxantrone Hydrochloride

## Key facts

- **NCT ID:** NCT03531918
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531918, "Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03531918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*